whitepaper
ebook: Habitat for disease – disrupting the tumour micro-environment
No tumour prevails on its own. Rather, every tumour needs a community to thrive.
List view / Grid view
Antibodies
article
Antibodies allow for a targeted approach to cancer therapy
Cancer can be an immovable beast, tenacious in its numerous mechanisms to thrive and grow. However, the healthcare industry has an ever-expanding arsenal of therapies designed to thwart it, with variable levels of success. Nikki Withers speaks to Dr Jill O’Donnell-Tormey, CEO and Director of Scientific Affairs at the Cancer…
article
The race to find a coronavirus treatment: are antibodies the answer?
At the beginning of March, US President Donald Trump pressed the pharmaceutical industry to “accelerate the development” of vaccines and therapies to contain the outbreak of the coronavirus pandemic. This article explores what is currently known about COVID-19 and potential treatments that are in the pipeline.
article
Not everyone loves surprises: know your ADC’s critical quality attributes
The importance of product characterisation throughout the entire drug development process cannot be understated. Success, money and lives depend on it. This article delves into why you need to understand every aspect of an ADC in order to prevent unwelcome surprises down the line.
whitepaper
Application note: A rapid method to quantitatively screen bispecific antibodies using Protein A and HIS1K biosensors
Scientists at Celgene Corporation developed a screening process incorporating the Octet® HTX system to identify pools and clones with higher concentrations of bispecific antibodies. Higher throughput was achieved from the multiple simultaneous measures possible on the Octet system and rapid assay times, such as binding optimisation in only 10 minutes.…
article
Expert view: Early product characterisation mitigates risks in biologics development
Developers of small molecule pharmaceuticals perform a battery of analytical tests before early clinical trials.
article
Expert view: Are you ready for next generation therapeutic antibodies?
Do not let the challenges of selecting and analysing bispecific antibodies create havoc in your antibody development.
article
Pooling research and development resources to tackle emerging threats
Here, Sheraz Gul highlights some encouraging displays of industry co-operation that aim to counter the global threat posed by COVID-19.
article
Expert view: The path to the high-hanging fruit: access to greater diversity and rapid down-selection
Therapeutic monoclonal antibodies are proven and effective treatment options but many of the ‘low-hanging fruit’ therapeutics have already been identified.
news
Human tuberculosis blood signal replicated in mice
More research into tuberculosis is now possible with the development of an optimisied mouse model that exhibits the same blood immune response to Mycobacterium tuberculosis infection as humans.
article
Antibodies In-Depth Focus 2020
This In-Depth Focus includes articles on antibodies as a treatment for COVID-19, the importance of understanding every aspect of an ADC and the potential of antibodies as a targeted cancer therapeutic.
article
Drug Target Review – Issue 1 2020
This issue includes a spotlight on how genomic assays could revolutionise healthcare, a discussion on how lab automation can improve drug discovery and an analysis of whether antibodies can provide an effective coronavirus treatment. Other article topics in this issue include immuno-oncology and artificial intelligence.
news
Collaboration to co-develop antibody products for treating COVID-19
AbCellera and Eli Lilly have announced their partnership to develop, manufacture and distribute antibody treatments for the COVID-19 coronavirus.
news
Antibodies stimulate microglia to degrade Alzheimer’s amyloid plaques
A novel antibody has been shown to stimulate microglia to degrade amyloid plaques in a murine model of Alzheimer’s disease.
article
Rebalancing the immune system to treat autoimmune disease
Dr Nicolas Poirier reveals how immunotherapies can be designed to recalibrate the immune system for long-term maintenance of autoimmune remission.